Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an
incidence relatively high in developed countries and rapidly growing in developing …

Ischemic heart disease is the greatest health burden and most frequent cause of death
worldwide. Myocardial ischemia/reperfusion is the pathophysiological substrate of ischemic …

Aims To investigate in-hospital and long-term prognosis in T2DM patients presenting with
acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents …

The treatment of myocardial infarction (MI) remains a substantial challenge due to excessive
inflammation, massive cell death, and restricted regenerative potential, leading to …

Cardiac diseases, such as myocardial infarction and heart failure, have become a major
clinical problem globally. The accumulating data demonstrate that bioactive compounds with …

Owing to recent advances in early reperfusion strategies, pharmacological therapy,
standardized care, and the identification of vulnerable patient subsets, the prognosis of …

For almost 30 years, urgent revascularization termed primary percutaneous coronary
intervention has been a cornerstone of modern care for acute myocardial infarction (AMI). It …

Myocardial infarction (MI) is the leading cause of death worldwide and can lead to the loss of
cardiac function and heart failure. Reactive oxygen species (ROS) play a key role in the …

A challenge in treating cardiac injury is the low heart-specificity of the drugs. Nanostructured
lipid carriers (NLCs) are a relatively new format of lipid nanoparticles which have been used …

Cardiac remodeling is a common consequence of cardiovascular diseases and is closely
associated with oxidative stress, inflammation, and apoptosis. Germacrone, a bioactive …